Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Pfizer Inc.    PFE   US7170811035

PFIZER INC. (PFE)

317
Delayed Quote. Delayed Nyse - 09/16 04:02:52 pm
30.05 USD   +0.43%
1d ago PFIZER : Mergers Watchdog Paves Way For 'Cable Fines'
1d ago AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug
1d ago PFIZER : Takeover Panel wants powers
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

11/19/2012 | 08:40am US/Eastern
Recommend:
0
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
Recommend :
0
React to this article
Latest news on PFIZER INC.
1d ago PFIZER : Mergers Watchdog Paves Way For 'Cable Fines'
1d ago AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug
1d ago PFIZER : Takeover Panel wants powers
2d ago PFIZER : Health and Human Services Department (HHS); Food and Drug Administratio..
2d ago Court dismisses lawsuit against Pfizer, Ranbaxy over generic Lipitor; says, d..
2d ago PFIZER : Police recover large quantity of counterfeit cream
2d ago PFIZER : South West Primary Care Network is the first in the UK to be chosen as ..
3d ago Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor
5d ago ESPERION THERAPEUTICS : TSRL Announces Appointment of President
5d ago PFIZER : 35 Nurse Leaders Graduate from the 201 ICN-Burdett Global Nursing Leade..
Advertisement
Chart
Duration : Period :
Pfizer Inc. Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Income Statement Evolution
Pfizer Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF